Article Text
Statistics from Altmetric.com
Over the last few weeks there have been several prominent stories in the national press about people being forced to pay for their NHS treatment because they have chosen to pay for supplemental private care. One case is that of Jack Hose, who has bowel cancer and was prescribed irinotecan on the NHS, but this treatment was not effective.1
Refusing to give up, Mr Hose was privately prescribed cetuximab in combination with irinotecan with some success. His local NHS trust has now informed him that if he continues to pay for private care, he will also have to pay for all his NHS care, including repaying the cost of his original irinotecan prescription. Alan Johnson has supported this stance, claiming that to do otherwise would create “a two-tier” NHS. In fact, this attitude is unethical and self-contradictory.
First, a two-tier NHS already exists inasmuch as some drugs are available in some areas but not in others because of trusts’ individual funding decisions. It is disingenuous to claim that a two-tier NHS is unacceptable when the notorious “postcode lottery” means that …
Footnotes
Funding: This research was internally funded by the University of Glasgow.
Competing interests: None.
Read the full text or download the PDF:
Other content recommended for you
- International experience of paying for expensive medicines
- A sixth of hospitals in England have expanded private patient options this year, the BMJ finds
- Should NHS patients be allowed to contribute extra money to their care?
- Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
- Targeted treatments in colorectal cancer: state of the art and future perspectives
- Patients in England are given green light to buy drugs privately alongside NHS care
- Will the fudge on equity sustain the NHS into the next millennium?
- A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment
- Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
- Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer